Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766586 | 0.79 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL4210668 | 0.79 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL4209190 | 0.78 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL4296523 | 0.77 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL17465971 | 0.76 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL12776122 | 0.75 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL5766810 | 0.74 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL4212630 | 0.73 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL11914746 | 0.72 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL4212490 | 0.71 | MAPK14 (0.46) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | claimed |
| EP-1781655-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | claimed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-1786811-A2 | TRIAZOLOPYRIDINE COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1781655-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018735-A2 | TRIAZOLOPYRIDINE COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209577-A1 | Novel Triazolopyridine Compounds | MAP3K2, MAP3K5, MAP3K9 | MAPK14 126/4885 |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | TNF, MAP3K2, MAP3K5 | MAPK14 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.